Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.

@article{Newman2012CosteffectivenessOF,
  title={Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.},
  author={Matthew Newman and Laura T Jones and Jacqueline M Kraft and Andrea W Lee and Garrett M Lech and Natalija M Farrell and Victor Phantumvanit and Roger A. Edwards},
  journal={Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners},
  year={2012},
  volume={18 4},
  pages={394-401}
}
PURPOSE To determine the cost-effectiveness of fulvestrant 250 mg compared to 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy. METHODS A Markov model was constructed to find the incremental cost-effectiveness of fulvestrant 250 mg monthly when compared with the 500… CONTINUE READING